ERIN SNEED: Open Payments
NPI 1770138539 · GARDEN GROVE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,791 in 77 payments from 7 companies in 2025. Trend: 2023 $778 · 2024 $1,254 · 2025 $1,791
Food & beverage: $1,690Education: $101
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $722 |
| Teva Pharmaceuticals USA, Inc. | 19 | $353 |
| E.R. Squibb & Sons, L.L.C. | 13 | $343 |
| Vanda Pharmaceuticals Inc. | 12 | $176 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Janssen Pharmaceuticals, Inc | 1 | $33 |
| Alkermes, Inc. | 1 | $15 |
Products named: INGREZZA, COBENFY, UZEDY, FANAPT, REXULTI, ABILIFY MAINTENA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
